Journal of Geriatric Psychiatry and Neurology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wint, D. P.
Right arrow Articles by Fernandez, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wint, D. P.
Right arrow Articles by Fernandez, H. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Geriatric Psychiatry and Neurology, Vol. 17, No. 3, 127-136 (2004)
DOI: 10.1177/0891988704267457

Psychosis in Parkinson’s Disease

Dylan P. Wint, MD

Departments of Psychiatry

Michael S. Okun, MD

Departments of Neurology

Hubert H. Fernandez, MD

Department of Neurology, McKnight Brain Institute/UF, 100 S. Newell Drive, PO Box 100236, Gainesville, FL 32610Fernandez{at}neurology.ufl.edu

Psychosis in Parkinson’s disease (PD) is a fairly common and vexing problem. Although it can occur at any stage of the illness, it is a particularly important issue for patients who are in the later stages of PD and have been chronically treated with anti-PD medications. The exact pathophysiology of PD-related psychosis remains a mystery. Neurochemical imbalances, sleep disturbances, and visual processing abnormalities in PD have been implicated in its pathogenesis. Treatment of psychotic symptoms should occur only after potential medical and environmental causes of delirium have been eliminated or addressed. Initial pharmacologic changes should include limiting the patient’s anti-PD medications to those that are necessary to preserve motor function. Should that fail, an atypical antipsychotic agent is presently the treatment of choice. An emerging treatment option is the use of acetylcholinesterase inhibitors. This article reviews what is known about the epidemiology, risk factors, pathophysiology, and treatment of PD-related psychosis. (J Geriatr Psychiatry Neurol 2004; 17:127-136)

Key Words: Parkinson • psychosis • antipsychotic • levodopa

References

  • 1. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease. Drug-induced psychiatric states. Adv Neurol 1995; 65:115-138.[Medline] [Order article via Infotrieve]
  • 2. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucination associated with Parkinson disease. Arch Neurol 1996; 53:1265-1268.[Abstract]
  • 3. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970; 23:193-200.[Medline] [Order article via Infotrieve]
  • 4. Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001; 70:727-733.[Abstract/Free Full Text]
  • 5. Fénelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123:733-745.[Abstract/Free Full Text]
  • 6. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64:533-535.[Abstract/Free Full Text]
  • 7. Aarsland D, Larsen JP, Cummins JL. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56:595-601.[Abstract/Free Full Text]
  • 8. Sadock BJ, Sadock VA, eds. Kaplan and Sadock’s comprehensive textbook of psychiatry seventh edition on CD-ROM. Philadelphia: Lippincott Williams & Wilkins, 2000.
  • 9. Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Parkinson’s Study Group. Mov Disord 1998; 13:20-28.[CrossRef][Medline] [Order article via Infotrieve]
  • 10. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993; 43:2227-2229.[Abstract/Free Full Text]
  • 11. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 1995; 45(4):669-671.[Abstract/Free Full Text]
  • 12. Goetz CG, Leurgans S, Pappert EJ, et al. Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 2001; 57:2078-2082.[Abstract/Free Full Text]
  • 13. Melamed E. Neurobehavioral abnormalities in Parkinson’s disease. In:Watts RL, Koller WC, eds. Movement disorders. New York: McGraw Hill, 1996:257-262.
  • 14. Goetz CG, Vogel C, Tanner CM, et al. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998; 51(3):811-814.[Abstract/Free Full Text]
  • 15. Rinne UK. Deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand 1983; 95(suppl):107-111.
  • 16. Tanner CM, Vogel C, Goetz CG, et al. Hallucinations in Parkinson’s disease: a populational study. Ann Neurol 1983; 14:136-136.
  • 17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.[CrossRef][Medline] [Order article via Infotrieve]
  • 18. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. J Neural Transm 2000; 107:59-71.[CrossRef]
  • 19. Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 1978; 43:143-151.
  • 20. Pappert EJ, Goetz CG, Niederman FG, et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov Disord 1999; 14:117-121.[CrossRef][Medline] [Order article via Infotrieve]
  • 21. Glenthøj BY, Hemmingsen R. Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21:23-46.[CrossRef][Medline] [Order article via Infotrieve]
  • 22. Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 1973; 29:35-40.[Medline] [Order article via Infotrieve]
  • 23. Sato M, Chen CC, Akiyama K, et al. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983; 18:429-440.[Medline] [Order article via Infotrieve]
  • 24. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992; 18:115-122.
  • 25. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2001; 70:734-738.[Abstract/Free Full Text]
  • 26. Klein C, Kömpf D, Pulkowski U, et al. A study of visual hallucinations in patients with Parkinson’s disease. J Neurol 1997; 244:371-377.[CrossRef][Medline] [Order article via Infotrieve]
  • 27. Aghajanian G, Marek G. Serotonin and hallucinogens. Neuropsychopharmacology. 1999; 21(suppl 1):S16-S23.[Medline] [Order article via Infotrieve]
  • 28. Liechti ME, Saur MR, Gamma A, et al. Psychological and physiological effects of MDMA ("ecstasy") after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000; 23:396-404.[CrossRef][Medline] [Order article via Infotrieve]
  • 29. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60(suppl 10):5-14.
  • 30. Perry EK, Perry RH. Acetylcholine and hallucinations: diseaserelated compared to drug-induced alterations in human consciousness. Brain Cognit 1995; 28:240-258.[CrossRef][Medline] [Order article via Infotrieve]
  • 31. Whitehouse PJ. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease. Adv Neurol 1986; 45:393-396.
  • 32. Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol 1984; 15:415-418.[CrossRef][Medline] [Order article via Infotrieve]
  • 33. Goetz CG, Tanner CM, Klawans MD. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139(4):494-497.[Abstract/Free Full Text]
  • 34. Perry E, Walker M, Grace J, et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22:273-280.[CrossRef][Medline] [Order article via Infotrieve]
  • 35. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135:669-675.[Abstract/Free Full Text]
  • 36. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson’s disease. Neurology 2000; 55:281-288.[Abstract/Free Full Text]
  • 37. Manni R, Pacchetti C, Terzaghi M, et al. Hallucinations and sleep-wake cycle in PD. Neurology 2002; 59:1979-1981.[Abstract/Free Full Text]
  • 38. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci 1990; 13:296-302.[CrossRef][Medline] [Order article via Infotrieve]
  • 39. Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson’s disease. Parkinsonism Relat Disord 2003; 9:S83-S89.
  • 40. Diederich NJ, Goetz CG, Raman R, et al. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol 1998; 21:289-295.[Medline] [Order article via Infotrieve]
  • 41. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 2002; 59:1249-1252.[Abstract/Free Full Text]
  • 42. Barnes J, Boubert L, Harris J, et al. Reality monitoring and visual hallucinations in Parkinson’s disease. Neuropsychologia 2003; 41:565-574.[CrossRef][Medline] [Order article via Infotrieve]
  • 43. Goetz, CG. Hallucinations and parkinsonism. Key note address. Presented at: Seventeenth Annual Symposia on Etiology Pathogenesis and Treatment of Parkinson’s Disease and Other Movement Disorders. October 19, 2003; Parkinson Study Group Meeting.
  • 44. Diederich NJ, Alesch F, Goetz CG. Visual hallucinations induced by deep brain stimulation in Parkinson’s disease. Clin Neuropharmacol 2000; 23(5):287-289.[CrossRef][Medline] [Order article via Infotrieve]
  • 45. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12:483-496[CrossRef][Medline] [Order article via Infotrieve]
  • 46. Friedman JH. The management of levodopa psychoses. Clin Neuropharmacol 1991; 14:283-295.[Medline] [Order article via Infotrieve]
  • 47. Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 1999.
  • 48. Friedman JH, Fernandez HH. The non-motor problems of Parkinson’s disease. Neurology 2000; 6:18-27.
  • 49. Romrell J, Fernandez HH, Okun MS. Rationale for current therapies in Parkinson’s disease. Expert Opin Pharmacother 2003; 4:1747-1761.[Medline] [Order article via Infotrieve]
  • 50. Fernandez HH, Trieschmann ME, Friedman JH. The treatment of psychosis in Parkinson’s disease: safety considerations. Drug Saf 2003; 26:643-659.[CrossRef][Medline] [Order article via Infotrieve]
  • 51. Fernandez HH, Trieschmann ME, Okun MS. "Rebound psychosis": effect of discontinuation of antipsychotics in Parkinson’s disease. Mov Disord, in press.
  • 52. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2 and serotonin 2 pK values. J Pharmacol Exp Ther 1989; 251:238-246.[Abstract/Free Full Text]
  • 53. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 151:201-211.
  • 54. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986; 73:295-297.[Medline] [Order article via Infotrieve]
  • 55. Fischer P, Danielczyk W, Simanyi M, Streifler MB. Dopaminergic psychosis in advanced Parkinson’s disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Advances in neurology, vol 53. Parkinson’s disease: anatomy, pathology and therapy. New York: Raven; 1990:391-397.
  • 56. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson’s disease. Mov Disord 1990; 5:225-229.[CrossRef][Medline] [Order article via Infotrieve]
  • 57. Friedman JH, Lannon MC. Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology 1997; 4:1077-1081.
  • 58. Bonnucelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson’s disease tremor: effects of acute and chronic administration. Neurology 1997; 49:1587-1590.[Abstract/Free Full Text]
  • 59. Jansen ENH. Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol Scand 1994; 89:262-265.[Medline] [Order article via Infotrieve]
  • 60. Wolters ECH, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40:832-834.[Abstract/Free Full Text]
  • 61. Parkinson Study Group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340:757-763.[Abstract/Free Full Text]
  • 62. French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet 1999; 353:2041-2042.[CrossRef][Medline] [Order article via Infotrieve]
  • 63. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. In: Narabayashi N, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology, Parkinson’s disease: from basic research to treatment. New York: Raven, 1993:702-706.
  • 64. Rudolf J, Grond M, Neveling M, Heiss W. Clozapine-induced agranulocytosis and thrombocytopenia in a patient with dopaminergic psychosis. J Neural Transm 1997; 104:1305-1311.[CrossRef]
  • 65. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson’s disease: an evidence based review. Mov Disord 2002; 17:S120-S127.
  • 66. Fernandez HH, Donnelly EM, Friedman JH. Long-term out-come of clozapine use for psychosis among parkinsonian patients. Mov Disord, in press.
  • 67. Arnt J, Skarsfeld T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropharmacology 1998; 18:63-101.
  • 68. Grant S, Fiton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 43:456-460.
  • 69. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson’s disease [letter]. Mov Disord 2001; 17:221-225.[CrossRef]
  • 70. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2000; 12:364-369.
  • 71. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52:782-785.[Abstract/Free Full Text]
  • 72. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanza-pine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085-1109.[CrossRef][Medline] [Order article via Infotrieve]
  • 73. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmens PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1996; 47:1085-1087.[Abstract/Free Full Text]
  • 74. Jimenez-Jimenez FJ, Talon-Barranco A, Orti-Pareja et al. Olanzapine can worsen Parkinsonism. Neurology 1998; 50:1183-1184.
  • 75. Friedman JH, Goldstein SM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 1998; 50:1195-1196.
  • 76. Aarsland D, Larsen JP, Lim NG, Tandberg E. Olanzapine for psychosis in patients with Parkinson’s disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999; 11:392-394.[Abstract/Free Full Text]
  • 77. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55:789-794.[Abstract/Free Full Text]
  • 78. Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000; 55:795-799.[Abstract/Free Full Text]
  • 79. Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson sensitive populations. J Geriatr Psychiatr Neurol 2002; 15:156-170.
  • 80. Reddy S, Factor S, Molho E, Feustel P. The effect of quetiapine on psychosis and motor function in patients with and without dementia. Mov Disord 2002; 17:676-681.[CrossRef][Medline] [Order article via Infotrieve]
  • 81. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term quetiapine use for drug induced psychosis among parkinsonian patients. Mov Disord 2003; 18:510-515.[CrossRef][Medline] [Order article via Infotrieve]
  • 82. Ondo WG, Vuong KD, Ringholz G. Quetiapine for drug-induced psychosis in Parkinson’s disease: a double-blind, placebo-controlled, parallel trial. Mov Disord 2003; 18:1083-1083.
  • 83. Morgante L, Epifano A, Spina E, et al. Quetiapine versus cloza-pine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci 2002; 23(Suppl 2):S89-S90.
  • 84. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002; 8:81-98.
  • 85. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson’s disease: preliminary experience. Clin Neuropharmacol, in press.
  • 86. Cunningham D, Hawthorn J, Pople A, et al. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 1987; 1:1461-1463.[Medline] [Order article via Infotrieve]
  • 87. White A, Corn TH, Feetham C, Faulconbridge C. Ondansetron in treatment of schizophrenia [letter]. Lancet 1991; 337:1173-1173.[Medline] [Order article via Infotrieve]
  • 88. Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 1992; 13:116-121.[CrossRef][Medline] [Order article via Infotrieve]
  • 89. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45:1305-1308.[Abstract]
  • 90. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996; 47:1608-1609.[Free Full Text]
  • 91. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10:229-238.[CrossRef][Medline] [Order article via Infotrieve]
  • 92. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1996; 61:324-325.
  • 93. Ott BR, Lannon MC. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 1992; 15:322-325.[CrossRef][Medline] [Order article via Infotrieve]
  • 94. Albuquerque EX, Santos MD, Alkondon M, et al. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15:S19-S25.
  • 95. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003; 18:937-941.[CrossRef][Medline] [Order article via Infotrieve]
  • 96. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16:1171-1195.[CrossRef][Medline] [Order article via Infotrieve]
  • 97. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin 2002; 18:258-264.[CrossRef][Medline] [Order article via Infotrieve]
  • 98. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036.[CrossRef][Medline] [Order article via Infotrieve]
  • 99. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol Sci 2002; 23:41-43.[CrossRef][Medline] [Order article via Infotrieve]
  • 100. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J Geriatr Psychiatry Neurol 2003; 16:184-188.[Abstract]
  • 101. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72:708-712.[Abstract/Free Full Text]
  • 102. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314.[Abstract/Free Full Text]
  • 103. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry 2003; 18:988-993.[CrossRef][Medline] [Order article via Infotrieve]
  • 104. Onofrj M, Thomas A. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 2003; 61:1452-1452.[Free Full Text]
  • 105. Hoflich G, Burghof KW, Kasper S, Moller HJ. Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson disease [abstract]. Nervenarzt 1994; 65:202-205.[Medline] [Order article via Infotrieve]
  • 106. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson’s disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15:32-34.[Medline] [Order article via Infotrieve]
  • 107. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Mov Disord 2003; 18:831-832.[CrossRef][Medline] [Order article via Infotrieve]
  • 108. Wykes T, Parr A, Landau S. Group treatment of auditory hallucinations. Exploratory study of effectiveness. Br J Psychiatry 1999; 175:180-185.[Abstract/Free Full Text]
  • 109. Lee K, Hannan C, van den Bosch JA, et al. Evaluating a hearing voices group for older people: preliminary findings [letter]. Int J Geriatr Psychiatry 2002; 17:1079-1080.[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
D Aarsland, K Bronnick, U Ehrt, P P De Deyn, S Tekin, M Emre, and J L Cummings
Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress
J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 36 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
B R Thanvi, T C N Lo, and D P Harsh
Psychosis in Parkinson's disease
Postgrad. Med. J., October 1, 2005; 81(960): 644 - 646.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wint, D. P.
Right arrow Articles by Fernandez, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wint, D. P.
Right arrow Articles by Fernandez, H. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?